CS-NEURO-1
Pre-clinical- Indications
- Neurobehavioral disorders
Company intelligence / Profile preview
Cannabis Science focused on developing cannabinoid-based pharmaceuticals for serious illnesses including skin cancers and HIV/AIDS. The company had several preclinical/early-stage programs but did not achieve FDA approval for any therapy before its SEC license was revoked in October 2019. It engaged in multiple academic collaborations but has not reported recent clinical results or commercial launches.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cannabis Science, Inc..